Why DexCom Stock Is Trading Lower Friday
Why DexCom Stock Is Trading Lower Friday
As for guidance, DexCom sees third quarter revenue between $975 million and $1 billion versus analyst estimates of $1.15 billion. Dexcom sees revenue for the 2024 fiscal year between $4 billion and $4.05 billion versus analyst estimates of $4.33 billion. DexCom, Inc. (NASDAQ:DXCM) shares are moving lower Friday after the company reported worse-than-expected second quarter revenue and issued weak guidance.
德康医疗股份有限公司（NASDAQ:DXCM）股价周五下跌，因公司报告第二季度营收低于预期并发出疲弱业绩预报。
What Happened: DexCom reported 2024 fiscal year second quarter earnings after the market closed on Thursday. The company reported adjusted EPS of 43 cents beating analyst estimates of 39 cents.
发生了什么：DexCom在周四收盘后报告了2024财年第二季度财报。公司报告每股调整后的收益为43美分，超过分析师预估的39美分。
DexCom also reported quarterly revenue of $1.04 billion missing analyst estimates of $1.36 billion. This figure represents a 15% year-over-year growth.
DexCom还报告称季度营收为10.4亿美元，低于分析师预估的13.6亿美元。这一数字代表了15%的年增长。
As for guidance, DexCom sees third quarter revenue between $975 million and $1 billion versus analyst estimates of $1.15 billion. Dexcom sees revenue for the 2024 fiscal year between $4 billion and $4.05 billion versus analyst estimates of $4.33 billion.
至于业绩预报，DexCom预计第三季度营收为0.975亿美元至10亿美元，而分析师预估为11.5亿美元。Dexcom预计2024财年营收为40亿美元至40.5亿美元，而分析师预估为43.3亿美元。
Dexcom included several highlights from the second quarter in its earnings report, including securing coverage for Dexcom ONE in France for certain people with type 2 diabetes and it launched Direct-to-Watch in the U.S. and several other markets worldwide.
Dexcom在其财报中列出了第二季度的一些亮点，包括在法国为某些2型糖尿病患者获得Dexcom ONE的覆盖，并在美国和全球其他几个市场推出了Direct-to-Watch。
"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," said Kevin Sayer, Dexcom's chairman, president and CEO.
“虽然Dexcom在第二季度推进了几个关键战略计划，但我们的执行没有达到我们的高标准，”德康医疗主席、总裁兼首席执行官Kevin Sayer说道。
"We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth."
“我们有一个独特的机会，用我们的差异化产品组合为全球数百万客户服务，我们正在采取行动改善我们的执行并最好地为持续的长期增长做好准备。”
Analyst Changes: Following the earnings report, multiple analysts issued price target changes.
分析师变化：发布财报后，多个分析师发布了价格目标的变化。
- JP Morgan analyst Robbie Marcus downgrades DexCom from Overweight to Neutral and lowers the price target from $145 to $75.
- Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and lowers the price target from $145 to $89.
- Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $145 to $80.
- RBC Capital analyst Shagun Singh maintains DexCom with a Outperform and lowers the price target from $165 to $145.
- Piper Sandler analyst Matt O'Brien maintains DexCom with a Overweight and lowers the price target from $150 to $90.
- JP摩根分析师Robbie Marcus将德康医疗的评级从超配降至中立，并将价格目标从145美元降至75美元。
- Canaccord Genuity分析师William Plovanic维持德康医疗的买入评级，并将价格目标从145美元降至89美元。
- 威尔斯·法戈分析师Larry Biegelsen维持德康医疗的超配评级，并将价格目标从145美元降至80美元。
- RBC Capital分析师Shagun Singh维持对德康医疗的跑赢大市评级，并将价格目标从165美元降至145美元。
- 派杰投资分析师Matt O'Brien维持德康医疗的超配评级，并将价格目标从150美元降至90美元。
DXCM Price Action: At the time of writing, DexCom stock is trading 40.2% lower at $64.45 per data from Benzinga Pro.
DXCM股票目前正以64.45美元的价格交易，跌幅为40.2%，数据来源于Benzinga Pro。
Image: Courtesy of DexCom
图片：DexCom提供的图像。
